XiaoMi-AI文件搜索系统
World File Search SystemSAIL66
Sail66正在开发CLDN6阳性固体癌症
A prominent academic journal in the field of cancer immunotherapy has adopted the non-clinical research results of SAIL66, which uses the Dual-Ig technology, a unique antibody engineering technology made by Chugai Pharmaceutical, Non-clinical research suggests that SAIL66 has high selectivity for CLDN6 (claudin 6), and that it may exhibit a higher antitumor effect compared to conventional T-cell engagers by costimulating CD3和CD137目前，正在对CLDN6阳性固体癌
chugai's Sail66，正在开发CLDN6阳性实体瘤，非临床研究结果发表在《癌症免疫疗法》杂志上
chugai's Sail66，正在开发CLDN6阳性实体瘤，非临床研究结果发表在《癌症免疫疗法》杂志上